[225Ac]Ac-DOTA-2Rs15d

N/A

Report date: 2025/11/04 16:07:46

Base Information

Drug Name[225Ac]Ac-DOTA-2Rs15d

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Radiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInstitute of Nuclear Chemistry and Technology

China Registration ClassN/A

Develop Information

Active CompaniesInstitute of Nuclear Chemistry and Technology

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A